Propanc Biopharma, Inc. develops proenzyme-based therapeutics for chronic diseases, including recurrent and metastatic cancer. Its lead asset, PRP, is an intravenous formulation of trypsinogen and chymotrypsinogen designed to target cancer stem cells, epithelial-mesenchymal transition, tumor angiogenesis, migration, and cancer cell death in solid tumors such as pancreatic and ovarian cancer.
Company news commonly covers PRP preclinical data, clinical-development preparations, pharmacokinetic assay work, GMP and trial-enabling activities, intellectual-property filings for proenzyme formulations and production methods, and research collaborations with the Universities of Jaén and Granada. Updates also include corporate financing, preferred-stock transactions, and periodic financial results.
Propanc Biopharma announced significant findings from Ms. Belen Toledo's thesis on proenzyme therapy for solid tumors. The research shows that proenzymes not only target cancer stem cells but also normalize the tumor microenvironment, promoting cell differentiation and potentially reversing malignant tumor phenotypes. These results, deemed pivotal by Chief Scientific Officer Dr. Julian Kenyon, support advancing their lead candidate, PRP, into clinical trials. The study is part of the POP1 program aimed at producing synthetic proenzymes at commercial scale, enhancing the company's innovative cancer treatment approach.
Propanc Biopharma, Inc. (OTCQB: PPCB) has entered into an equity purchase facility of up to $5 million with Dutchess Capital Growth Fund LP. The funds will support operations and advance the lead product, PRP, towards a First-In-Human study for advanced cancer patients. The company plans to establish a US-based R&D subsidiary, Cellmed Bio LLC, to identify strategic partnerships. The share issuance will be at a discount, with the right to sell shares contingent upon registering with the SEC. A registration statement will be filed within 45 days.
Propanc Biopharma, a biopharmaceutical company focused on cancer treatments, has appointed Paul Patrizio as Strategic Advisor to its executive team. He will facilitate the establishment of Cellmed Bio LLC, a wholly-owned research and development subsidiary in New Jersey, aimed at advancing the company's lead candidate, PRP, into clinical trials for metastatic cancer. This initiative is expected to enhance financing capabilities and resource allocation for clinical development.
Propanc Biopharma (OTCQB: PPCB) announced new research published in Expert Opinion on Biological Therapy, confirming the anti-tumor efficacy of pancreatic proenzymes, trypsinogen and chymotrypsinogen. The study shows these proenzymes can sensitize cancer stem cells (CSCs), enhancing the effectiveness of standard treatments like chemotherapy. Key findings include reduced CSC proliferation and migration, induction of cell differentiation, impaired angiogenesis, and decreased metastatic potential. The research supports proenzymes as a potential adjuvant therapy for late-stage cancer patients.
Propanc Biopharma, Inc. (OTCQB: PPCB) provided a shareholder update, highlighting confidence in a post-pandemic recovery. With improved economic conditions, the company is focusing on capital restructuring and advancing its lead product, PRP, towards a Phase I clinical study. The update emphasizes significant progress in scientific research, particularly in proenzyme therapy, and anticipates cash-back benefits from the Australian government for R&D. Strong institutional support is noted, alongside new therapeutic discoveries aimed at combating aggressive cancer types.
Propanc Biopharma, Inc. (OTCQB: PPCB) has reported promising results from its Proenzymes Optimization Project 1 (POP1), which indicates that pancreatic proenzymes may inhibit cancer spread and improve outcomes for patients with metastatic cancers. Professor Juan Marchal, a key advisor, predicts that these findings could lead to effective new treatments. The company is looking to initiate Phase II clinical studies in Spain for pancreatic and ovarian cancers after completing Phase I trials in Australia. Propanc aims to develop a superior clinical compound for commercial use while partnering with leading universities.
Propanc Biopharma, Inc. (OTCQB: PPCB) announced the appointment of Ms. Belen Toledo MSc., a biotechnologist, to lead research on the impact of proenzyme therapy on the tumor microenvironment as part of the Proenzymes Optimization Project 1 (POP1). The project aims to produce commercial quantities of trypsinogen and chymotrypsinogen without animal sourcing. The research, conducted with the University of Granada, utilizes 3D tumor models to assess proenzyme therapy's effects on cancer cells while sparing healthy cells, enhancing prospects for effective cancer treatments.
Propanc Biopharma (OTC: PPCB) has received expressions of interest from oncologists at the University Hospital of Jaén to evaluate its proenzyme therapy for preventing recurrence and metastasis in pancreatic and ovarian cancers. This evaluation will likely lead to Phase IIa proof of concept studies for each indication, following a planned Phase Ib study in 2021 at the Peter Mac Cancer Center. The company aims to conduct trials in Europe due to the larger patient population, indicating a strategic move to enhance its clinical research footprint.
Propanc Biopharma (OTC: PPCB) is on a mission to revolutionize cancer treatment by analyzing the efficacy of pancreatic proenzymes versus T-Cell therapy for solid tumors like pancreatic, ovarian, and colorectal cancers. Led by CEO James Nathanielsz and researcher Professor Macarena Perán, the company aims to enhance patient survival and reduce treatment toxicity. Their novel cell differentiation therapy targets cancer stem cells, potentially offering a safer, more effective solution compared to traditional therapies, while the eye-watering costs of T-Cell therapies remain a concern.
Propanc Biopharma, Inc. (OTC: PPCB) has advanced its Proenzymes Optimization Project 1 (POP1) aimed at producing large quantities of proenzymes trypsinogen and chymotrypsinogen for cancer treatment. The global metastatic cancer treatment market is expected to reach US$111.2 billion by 2027. Lead researcher Aitor González has successfully synthesized and purified these proenzymes, which will be further scaled at the MEDINA Foundation. CEO James Nathanielsz emphasized the goal to create less toxic cancer treatment options, while Dr. Julian Kenyon highlighted progress in developing synthetic versions.